Introduction {#Sec1}
============

Immune-mediated inflammatory diseases (IMIDs) refer to a group of chronic conditions that share common inflammatory pathways \[[@CR1]\]. IMIDs include conditions such as inflammatory bowel disease (IBD), psoriasis (PS) and rheumatologic conditions (RC) including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). IMIDs affect approximately 5--7% of Western populations and can have a detrimental effect on quality of life and health outcomes \[[@CR1]\]. In line with other chronic conditions, sub-optimal adherence to treatment has been reported in a number of systematic reviews. Persistence or adherence rates to treatments for IMIDs were found to range from 30% to 80% in RA \[[@CR2]\], 7% to 72% in IBD \[[@CR3]\], and 33% to 78% in PS \[[@CR4]\].

Increasing adherence may have a far greater impact on health outcomes than advances in medical treatments \[[@CR5], [@CR6]\]. There are also associated economic implications such as increased medication costs, resources used including hospital admissions, inadequate use of healthcare professionals' time, and increased sickness-related work absence \[[@CR7]\]. Thus, understanding the key drivers of non-adherence to the types of treatments used across IMIDs is an important area of investigation and key for the development of effective strategies to tackle non-adherence. Further, the identification of generic tools and/or interventions common to IMIDs would enable the identification of key areas likely to be important for adherence and assist the clinician to identify and address patient concerns in their consultations.

Although there are existing systematic reviews looking at factors associated with non-adherence in the individual clinical areas (i.e., RA, IBD, or PS), there is a clear need for a broad understanding of the determinants of adherence across IMIDs \[[@CR2]--[@CR4], [@CR8]--[@CR19]\].

Aims {#Sec2}
====

To our knowledge, no systematic review to date has examined factors associated with adherence across several IMIDs or included multiple treatment types. The purpose of the current review is, therefore, to examine factors associated with adherence in selected IMIDs across rheumatology, gastroenterology and dermatology in a systematic way. This could enable the identification of associations not only in each therapeutic area but also those in common across the therapeutic areas. Identification of key factors will allow interventions to focus on areas most likely to have an impact on non-adherence. If there are factors that are found to be common across these IMIDs, this will afford the opportunity to develop cross-condition tools for the health care professional (HCP) both to identify areas of non-adherence risk and for generic interventions, which may be particularly useful for rheumatologists who are likely to treat patients with different manifestations of their IMIDs.

Methods {#Sec3}
=======

The systematic review followed guidelines developed by the National Institute for Clinical Excellence (NICE) and the Centre for Reviews and Dissemination, University of York \[[@CR18], [@CR19]\].

Literature Search and Selection {#Sec4}
-------------------------------

A search of the literature was conducted via the following online databases: PubMed, Science Direct, PsychINFO and the Cochrane Central Register of Clinical Trials. A broad search strategy was developed to capture each disease within the examined clinical areas (see Fig. [1](#Fig1){ref-type="fig"}). In addition, the reference lists of relevant articles identified through the database search and existing systematic reviews were searched manually to identify further suitable studies. The search was limited to articles published from January 1, 1980 to February 14, 2014. The reason for limiting the search to articles published after January 1980 was that a previous systematic review identified that general research interest in treatment adherence began around 1980 \[[@CR3]\].Fig. 1Search terms

The search was conducted individually for each of the selected IMIDs within the five clinical areas: RA, AS, PsA and IBD and PS. Initially, the titles and abstracts of the articles identified through the search strategies were screened by a first reviewer for eligibility (SB, AF or DB). The full text was then obtained for all shortlisted studies and independently reviewed by a second reviewer (AB). Disagreements between the two reviewers were resolved by discussion and independently assessed by a third reviewer (EV or JW).

Inclusion/Exclusion Criteria {#Sec5}
----------------------------

Studies were eligible for inclusion in the review if they met all the criteria below:Published/in press between January 1, 1980 and February 14, 2014.Written in English language.Included patients with a diagnosis of RA, AS or PsA, IBD, or PS.Based primarily on adult samples (≥18 years).Included statistics to examine associations of factors with non-adherence.Used a specified measure of adherence (validated or non-validated).Included adherence measurement of injection or infusion, oral, rectal or transdermal formulation (excluding parenteral nutrition).Contained primary quantitative data.All participants were on a disease-specific treatment.Full study published in a peer-review journal (i.e., not a conference abstract).

Studies in other clinical indications were included as long as specific information on one of the conditions of interest was explicit within the results. The decision was taken to exclude studies examining adherence to topical treatments alone, as topical treatments are not used across all three clinical areas and are typically prescribed in mild cases of PS only.

Quality Appraisal {#Sec6}
-----------------

Quality assessment was carried out for each study to examine their susceptibility to bias in terms of rigor, methods and analysis. A 16-item quality checklist adapted from a previous systematic review of a similar nature \[[@CR3]\] based on guidance from NICE and Strengthening the Reporting of Observational studies in Epidemiology was completed for each study. Although studies were not excluded or ranked according to quality, an overall quality score, based on the total number of quality criteria met, was computed for each study. Quality scores were used as general indicators for each study and are presented in the overview tables of included studies. Common quality limitations are explored in more detail in the "[Results](#Sec9){ref-type="sec"}" section.

Data Extraction and Synthesis {#Sec7}
-----------------------------

Studies identified through each individual search were combined for data synthesis and extraction. For each eligible study, data were extracted by the first reviewer using a standardized form consisting of 23 items, which included details of measures that could potentially relate to non-adherence. Details of the sample, non-adherence measure and potential associates examined were extracted and tabulated by the first reviewer and verified by the second and third reviewers. There was an 85% initial agreement in the data extracted and all discrepancies were resolved through discussion between the reviewers.

Due to the heterogeneity of the included studies, it was not possible to perform a meta-analysis of the findings. Frequencies and proportions of studies examining similar variables and any association observed were calculated to offer a simple indication of the level of evidence. As such, the evidence was primarily synthesized in a narrative review and quantified in terms of the proportions of studies finding an association. As no two studies controlled for the same variables and the quality of these studies varied considerably, preference was not given to findings from adjusted analyses. Where associations were found for a factor and these were all in the same direction, the association was considered to be consistent.

Compliance with Ethical Guidelines {#Sec8}
----------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec9}
=======

Included Studies {#Sec10}
----------------

A total of 73 studies met the inclusion criteria and were included in the combined review: RC = 26 (RA = 23; AS = 1; PsA = 11); IBD = 36; PS = 11 \[[@CR20]--[@CR92]\]. Details regarding the study selection and exclusion process followed are presented in Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. A summary of the characteristics of the studies and the factors examined in each study are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} Studies from the same authors were checked for overlapping samples, and where there was overlap in the samples, the studies examined different possible predictors of adherence \[[@CR69], [@CR70]\].Fig. 2Flowchart of included studies: rheumatologic conditions, reasons for exclusion of final 27 studies included: did not statistically examine factors associated with adherence (*n* = 8, original search) (*n* = 7, update search), full study data not reported (*n* = 1, original search), did not define measure of adherence (*n* = 9, original search) (*n* = 1, update search), intervention examined in relation to adherence (*n* = 1, original search)Fig. 3Flowchart of included studies: inflammatory bowel disease, reasons for exclusion of final 20 studies included: did not statistically examine factors associated with adherence (*n* = 10, original search) (*n* = 1, update search), did not define measure of adherence (*n* = 5, original search), intervention examined in relation to adherence (*n* = 2, original search), adherence examined in sample of pregnant women only (*n* = 2, original search)Fig. 4Flowchart of included studies: psoriasis reasons for exclusion of final 19 studies included: did not statistically examine factors associated with adherence (*n* = 7, original search) (*n* = 6, update search), examined topical treatments only (*n* = 5, original search), intervention examined in relation to adherence (*n* = 1, original search)Table 1Overview of included studies: rheumatologic conditionsAuthors and yearSample characteristics, origin, and designFactors measuredAnalysisNon-adherence: target, measure and extentDemographicClinicalTreatmentPsychosocialArturi et al. (2013)Sample: AS and RA outpatients\
*N*: 59AS and 53RA\
Mean age: AS: 47 (IQR = 33--57)\
Mean age: RA: 56 (IQR = 43.5--60)\
Male-AS: 73%\
Male-RA: 30%\
Origin: USA\
Design: cross-sectional\
Quality: 5/16 (31%)For AS and RA patients:\
age, gender,\
education\
insurance, employmentFor AS & RA patients\
Disease duration,\
Disease activity,\
Functional capacity, co-morbiditiesBoth AS and RA patients:\
medication typeFor AS only:\
DepressionUnivariate and multivariateTargetNSAIDs,\
Low dose oral steroids, DMARDs, aTNFMeasureCompliance questionnaire on Rheumatology (CQR)ExtentRA: 7%\
AS: 25%Beck et al. (1988)Sample: RA outpatients\
*N*: 63\
Mean age: 57.0 (SD = NR)\
Male: information not provided\
Origin: USA\
Design: cross-sectional\
Quality: 12/16 (75.0%)Age, **educational level**Symptoms (pain)Treatment dose (last and total), treatment cost, size of last meal, side effects, treatment coating, **time since last treatment**Intentions (**appointment keeping**, **treatment termination**, medication taking), pain reduction, **rarely missing** **school**, rarely missing work, accessibility (ease and length of time), follow through on commitmentsMultivariateTargetNSAID (Salicylate drugs)MeasureSerum salicylate assaysExtent50.7%Borah et al. (2009)Sample: Medical claims database (RA)\
*N*: 3829\
Mean age: 54 (SD = 12)\
Male: 25%\
Origin: US\
Design: retrospective cohort\
Quality: 7/11 (63.6%)Medication typeUnivariate and MultivariateTargetEtanercept, adalimumabMeasureMedication possession ratio (pharmacy claims data). Non- adherent classed as MPR \<80%Extent45.7%Brus et al. (1999)Sample: RA outpatients\
*N*: 65\
Mean age: 58.8 (SD = 12.1)\
Male: 32%\
Origin: The Netherlands\
Design: RCT\
Quality: 10/16 (62.5%)Age, gender, education levelSymptoms (pain), functional disability, disease activity**Self-efficacy**, treatment efficacy, environmental influences, practical barriers, social supportUnivariate and multivariateTargetDMARDS (Sulfasalazine therapy (SSZ))MeasurePill counts and pharmacy refillsExtent9% (SD = 12)---intervention group\
13% (SD = 22) control groupCaplan et al. (2013)Sample: Cohort of RA patients from ongoing longitudinal study\
*N*: 6052\
Mean age: 63.8 (SD = 12.17) Male: 19.7%\
Origin: USA\
Design: cross-sectional\
Quality: 6/16 (37.5%)**Age**, gender, marital status, ethnicity, education, **income**Functional status, visual problems, **co-morbidities**, disease durationMedication typeMemory problems, lifestyle (smoking), health literacy, social supportMultivariateTargetPrednisone, biologic treatment, DMARDMeasureMedication adherence self-report inventory (MASRI) visual analog scale. Good adherence: 80--120% in the last monthExtent20.4Chastek et al. (2012)Sample: PsA patients: claims data from commercial health plan\
*N*: 346\
Mean age: E: 45.6 (SD = 10.9)\
Mean age: A: 45.0 (SD = 10.3)\
Male: E 56.4%\
Male-A: 56.9%\
Origin: USA\
Design: retrospective cohort\
Quality: 7/12 (58.3%)Medication typeUnivariateTargetEtanercept or adalimumabMeasurePersistence: continuous use of index medication without gaps in therapy of at least 60 daysExtentNon-persistence: 50% etanercept\
55% adalimumabCho et al. (2012)Sample: RA patients: NHI claims database\
*N*: 388\
Mean age: 50.6 (SD = 14.9) Male: 17.5%\
Origin: Korea\
Design: retrospective cohort\
Quality: 7/12(58.3%)Gender, **age**, insurance type**Co-morbidities**, institution type (tertiary, regional, or general hospitals),\
physician type (**internist** versus other specialties)Medication typeDepressionTargetAdalimumab, etanercept, inFLiximabMeasureNon-persistence: a period longer than 14 weeks without a claim submitted for TNF inhibitorsExtentNon-persistence: 27% at 12 months\
39% at 18 monthsCurkendall et al. (2008)RA population: Commercial insurance claims from the MEDSTAT MarketScan Database\
*N*: 2285\
Mean age: 54 (SD = 12)\
Male: 25%\
Origin: US\
Design: retrospective cohort\
Quality: 8/11 (72.7%)**Gender**, **region**, **HMO insurance**MultivariateTargetEtanercept, adalimumabMeasureMedication possession ratio (pharmacy refill data)ExtentMean score (SD)\
0.52 (0.31)de Klerk et al. (2003)Sample: RA outpatients N: 81\
Mean age: 60 (SD = 14)\
Male: 34%\
Origin: The Netherlands\
Design: cohort\
Quality: 9/16 (56.4%)Age, **gender**, educational level, SESFunctional disabilitySide effects, **medication type**, **dosing frequencyHealth status**, health profile, perceived health status, **coping pattern**, **self-efficacy**, QoL, social supportMultivariateTargetNSAIDS (diclofenac and Naproxen) and DMARDS (SSZ and Methotrexate, MTX)Measure(MEMS)ExtentTaking non-compliance: 7--24%\
Incorrect dosing: 19--45%\
Timing non-compliance: 17--75%\
(Note: 2× medication class/4× medication type)de Thurah et al. (2010)Sample: RA outpatients\
*N*: 126\
Median age: 63.0 (range = 32--80)\
Male: 36%\
Origin: Denmark\
Design: cohort\
Quality: 10/16 (62.5%)Age, gender, educational levelFunctional disability, disease duration, co-morbiditiesTreatment dose (amount), concurrent medication**Treatment necessity,** **treatment concerns**Multivariate (prospective)TargetMTXMeasureSelf-reported questionnaires (CQ-R)Extent23.5% (0 months)\
23.1% (9 months)Garcia-Gonzalez et al. (2008)Sample: RA outpatients\
*N*: 70 (RA)\
Mean age: 53.9 (SD = 12.7)\
Male: 33%\
Origin: USA\
Design: cross-sectional\
Quality: 10/16 (62.5%)**Gender**, **ethnicity**, **educational level**Disease duration, disease activitySide effectsGeneral health statusUnivariateTargetDMARDs and/or biologic agents (drug names not stated)\
Self-reportedMeasureQuestionnaire (CQ-R)\
Mean score\
69.1ExtentReverse scored 0 (complete non-compliant-100 fully compliant)Martinez-Santana et al. (2013)Sample: RA outpatients\
*N*: 91\
Median age: 58 (SD = 12.3)\
Male: 27.5%\
Origin: Spain\
Design: retrospective longitudinal\
Quality: 7/16 (43.8%)**Age**, gender**Medication type**\
**Previous treatment** (previous exposure to aTNF drugs)MultivariateTargetAdalimumab, etanercept, infliximabMeasureProbability of not experiencing change of treatment over a 1 year periodExtent30%Muller et al. (2012)Sample: RA outpatients\
*N*: 1199\
Median age: 59.2 (SD = 13.1)\
Male: 17.3%\
Origin: Denmark\
Design: retrospective longitudinal\
Quality: 7/16 (44%)**Age**, gender, **employment status**, **education**, **income**, Residence status, languageDisease duration, co-morbidities, **number of healthcare visits** (to family doctor or rheumatologist), functional disability**Satisfaction with** **HCP,** **Information about RA, treatment scheme**, **Rheumatologist as source of RA information**UnivariateTargetRA medicationsMeasureSelf-report---Compliance: always\
took medication as prescribed\
Non-compliance: did not always take medication as prescribed, took less/more than prescribed, or mostly did not take the medicationExtentNon-compliance:\
Less than prescribed---14.8%\
More often than prescribed---1.6%\
Ignore doctor's recommendations: 1.7%Neame and Hammond (2005)Sample: RA outpatients\
*N*: 344\
Mean age: 49.5 years and over (mean age NR)\
Male: 33%\
Origin: UK\
Design: cross-sectional\
Quality: 10/16 (62.5%)Age, gender, SES, educational levelDisease duration, disease activityTreatment necessity, **treatment concerns**, disease and treatment understandingUnivariateTargetDMARDs (SSZ and MTX)MeasureSelf-reported question from RAIExtent8%Park et al. (1999)Sample: RA outpatients\
*N*: 120\
Age: 56.07 (SD = 12.74)\
Male: 21%\
Origin: USA\
Design: longitudinal\
Quality: 14/16 (87.5%)**Age**Anxiety, Depression, Cognitive factors **(latent cognitive variable,** **practical barrier (busyness), control of negative affect, pain control, general control**TargetNot specifiedMeasureMEMsExtent62% omission errors in 1 monthPascal-Ramos and Contreras-Yáñez (2013)Sample: RA outpatients\
*N*: 149\
Age: 38.5 (SD = 12.8)\
Male: 11%\
Origin: Mexico\
Design: cohort\
Quality: 9/14 (64.3%)Age, gender, residence status, occupation, marital status, insurance, **educationDisease activity**, co-morbidity, disease-specific autoantibodies (RF, **ACCP**), **functional disability, follow-up duration**Medication typeMotivation for non-persistence, **practical barriers---difficulty to find arthritis medicine and expense**MultivariateTargetDMARDsMeasureSelf-reported questionnaire (CQ)ExtentNP: 66.4%Pascual-Ramos et al. (2009)Sample: RA outpatients\
*N*: 75\
Age: 56.07 (SD = 12.74)\
Male: 16%\
Origin: Mexico\
Design: longitudinal cohort\
Quality: 7/14 (50.0%)**Age**, gender, years of education, SES, marital statusdisease duration, disease activity, co-morbidity, functional disabilityMedication type, previous treatment, treatment numberUnivariate (prospective)TargetDMARDs and corticosteroidsMeasureSelf-report (physician interview)Extent57.3%Quinlan et al. (2013)Sample: RA outpatients\
*N*: 125\
Age: 56.07 (SD = 12.74)\
Male: 17%\
Origin: USA\
Design: cross-sectional\
Quality: 9/16 (56.3%)Age, gender, **ethnicity**, education incomeDisease duration, treatment providerTotal prescribed medication**Patient-provider relationship** (involvement in medication decision making; confidence with contacting provider), health literacyBivariate and multivariateTargetRA medication, NSAIDs, Biologic agentsMeasureMMASExtentMean adherence score (SD) = 0.84 (0.21)Saad et al. (2009)Sample: Psoriatic arthritis\
*N*: 566\
Age: 45.7 (SD = 11.1)\
Male: 47%\
Origin: UK\
Design: cohort\
Quality: 6/16 (37.5%)Age, **gender**Disease duration, disease activity, **co-morbiditiesMedication type, other medicationsLifestyle (smoking), general health**Univariate and multivariate (prospective)TargetBiologics (inFLiximab, etanercept, adalimumab)MeasureHCP reported questionnaireExtent24.5%Spruill et al. (2014)Sample: RA outpatients\
*N*: 56\
Mean age: 51.5 (SD = 12.8)\
Male: 11%\
Origin: USA\
Design: cross-sectional\
Quality: 7/16 (44%)Age, gender, ethnicity, Education, insurance type**Disease duration**, **symptoms (pain**), disease activity, co-morbidities, functional disabilityMedication type, doseTreatment necessity, **treatment concerns, self-efficacy**Univariate and multivariableTargetMethotrexate, DMARD, biologics, corticosteroid, NSAIDMeasureMMASExtent37.5%Treharne et al. (2004)Sample: RA outpatients\
*N*: 85\
Mean age: 58.9 (SD = 12.6)\
Male: 26%\
Origin: UK\
Design: cross-sectional\
Quality: 11/16 (68.8%)Age, gender, marital status, number of children, **children living at home**, educational level, SES, spousal SESDisease duration, disease activity, co-morbidities**Number of medications**, **medication typeHCP--patient relationship**, social support, optimism, **treatment necessity**, **treatment concerns**Univariate and multivariateTargetDMARDs (MTX), NSAIDs, steroidsMeasureSelf-reported questionnaires (CQ-R) +2 items from the Reported Adherence to Medication (RAM)Extent5.8% unintentional\
9.4% intentional (assessed by the RAM)Tuncay et al. (2007)Sample: RA outpatients\
*N*: 100\
Mean age: 49.3 (SD = 11.8)\
Male: 15.1%\
Origin: Turkey\
Design: longitudinal\
Quality: 7/16 (43.8%)**Age**, gender, insurance statusDisease duration, disease activity, symptoms (morning stiffness), functional disabilityTreatment dose (number)---RA and overallNRUnivariateTargetDMARDs, NSAIDs, corticosteroidsMeasureSelf-reported questionnaireExtent11.6%van den Bemt et al. (2009)Sample: RA outpatients\
*N*: 228\
Mean age: 56.2 (SD = 12.2)\
Male: 32.5%\
Origin: Netherlands\
Design: cross sectional\
Quality: 13/16 (81.3%)Age, sex, marital status, education level**Disease duration,** functional disabilityNumber of medications, side effects**Treatment necessity**, treatment concern, **smoking**, disease and treatment understanding, coping patternUnivariateTargetDMARDsMeasurePharmacist interview.\
Self-reported questionnaire (CQ-R) and MARSExtent19% interview\
33% CQR\
60% MARSViller et al. (1999)Sample: RA outpatients\
*N*: 556\
Mean age: 52.9 (SD = 12.2)\
Male: 14%\
Origin: France, Netherlands, Norway\
Design: cohort\
Quality: 11/16 (68.8%)**Age, gender,** education levelDisease duration, symptoms (tenderness, inflammation), functional disabilityMedication type, surgery/injections, **side effects**Disease and treatment understanding, **HCP--patient relationship,** illness beliefs (severity, dependency, shame and adjustment)Multivariate (prospective)TargetNSAIDs, slow acting drug and corticosteroidsMeasureSelf-reported questionnaireExtent23.8% (18.9--44.5%)Wainmann et al. (2013)Sample: RA outpatients\
*N*: 107\
Mean age: 52.9 (SD = 12.2)\
Male: 14%\
Origin: USA\
Design: prospective cohort\
Quality: 8/14(57%)Age, **gender**, education, **marital status**, ethnicity, insurance type, employment status, income, household members, language**Functional disability (DMARD)**, disease duration, **disease activity** (DMARD), symptoms (pain), hand radiographsMedication type (Biologic agent use), Concomitant medication, **pill burden (pills per day (prednisone)Depression (DMARD)**, **H-QoL** social support, general health statusMultivariateTargetDMARDs, prednisoneMeasureMEMsExtentDMARDS- 36%\
Prednisone-30%Wong and Mulherin (2007)Sample: RA outpatients\
*N*: 68\
Mean age: 55.8 (SD = 13)\
Male: 40%\
Origin: UK\
Design: longitudinal\
Quality: 8/16 (50.0%)**Age**Symptoms (stiffness, pain, grip strength, swollen, tender joint count, disease activity, functional disabilityBeliefs about medication,\
HCP--patient relationship, **anxiety,** depression, social support (level/type)Multivariate (prospective)TargetDMARDs (SSZ, MTX, Hydroxychloroquine, intramuscular gold)MeasurePatient-held records and case notesExtent20%Factors assessed in relation to non-adherence were collated into four key categories: demographic; clinical; treatment and psychosocialFactors found to be associated with treatment adherence highlighted in bold*ACCP* anti--citrullinated protein antibodies, *AS* ankylosing spondylitis, *aTNF* anti-tumor necrosis factor, *CQ* choice questionnaire, *CQ-R* compliance questionnaire for rheumatology, *DMARD* disease-modifying anti-rheumatic drug, *HCP* health care professional, *HMO* health maintenance organization, *H-QoL* health-related quality of life, *IQR* interquartile range, *MARS* medication adherence report scale, *MEMS* medication event monitoring system, *MMAS* Morisky Medication Adherence Scale, *MPR* medication possession ratio, *MTX* methotrexate, *NHI* national health insurance, *NR* not recorded, *NSAID* non-steroidal anti-inflammatory drug, *PsA* psoriatic arthritis, *QoL* quality of life, *RA* rheumatoid arthritis, *RAI* rheumatology, allergy and immunology, *RAM* reported adherence to medication, *RCT* randomized controlled trial, *RF* rheumatoid factor, *SD* standard deviation, *SES* socioeconomic status, *SSZ* sulphasalazine therapy, *TNF* tumor necrosis factorTable 2Overview of included studies: IBDAuthors and yearSample characteristics, origin, and designFactors measuredAnalysisNon-adherence: target, measure and extentDemographicClinicalTreatmentPsychosocialBermejo et al. (2010)Sample: IBD outpatients\
*N*: 107\
Mean age: 41.3 (SD = 11)\
Male: 40%\
Origin: Spain\
Design: cross-sectional\
Quality: 7/16 (43.8%)Gender, marital statusDisease type, disease duration, disease activity, admissions/surgical procedures**Medication type,** **dosing frequencyDisease understanding**UnivariateTargetOral and topicalMeasureSelf-report questionnaireExtent69% (66% intentional/16% unintentional)Bernal et al. (2006)Sample: IBD outpatients\
*N*: 214\
Mean age: 40.3 (SD = 13.5)\
Male: 13%\
Origin: Spain\
Design: cross-sectional\
Quality: 4/16 (25.0%)Age, gender, employment status, educational levelDisease activity, disease duration, disease type, **disease severity**, disease related disabilityUnivariateTargetOral and topicalMeasureSelf-report questionnaireExtent43.5% (unintentional) 8% (intentional)Billioud et al. (2011)Sample: CD outpatients\
*N*: 108\
Median age: 35 (range 27--44)\
Male: 38%\
Origin: France\
Design: Cross-sectional\
Quality: 11/16 (68.8%)Age, gender, marital statusFamily history, **disease type,** **disease duration**, **relapse history**, age at diagnosis, previous investigations, past hospitalizationConcomitant treatment**, medication dose**Lifestyle (smoking)Univariate and multivariateTargetBiologics (adalimumab)MeasureSelf-reported questionnaire (reported missed or delayed injection)Extent45.5%Bokemeyer et al. (2007)Sample: CD outpatients\
*N*: 49\
Median age: 38 (range 17--68)\
Male: 49.2\
Origin: Germany\
Design: cross-sectional\
Quality: 9/16 (56.3%)Age, gender, employment statusDisease duration, disease activity, previous surgeryMedication dose, medication frequency, disease duration**Treatment concerns**UnivariateTargetOral NSAIDs (AZA)/5 ASAMeasureThiopurine *S*-methyltransferase (TPMT) and questionnaire (VAS)Extent9.2% (TPMT)and 7.1% (VAS)Carter et al. (2012)Sample: CD population, medical and pharmacy claims data\
*N*: 448\
Age: 42.6 (SD = 14.8)\
Male: 44%\
Origin: USA\
Design: retrospective observational cohort\
Quality: 9/16 (56.3%)Age, gender, regionOutpatient visits, number of hospitalizationsConcomitant medicationUnivariateTargetBiologic (Infliximab)MeasureMedication possession ratio ≥80%Extent23%Červený et al. (2007)Sample: IBD outpatients\
*N*: 177\
Mean age: 36.9 (SD NR)\
Male: 47.5%\
Origin: Poland\
Design: cross-sectional\
Quality: 5/16 (31.3%)Age, gender, marital status, educational level, employment statusDisease typeMedication typeLifestyle (smoking),UnivariateTargetIBD medications (all)MeasureSelf-reported interviewExtent38.9%Cerveny et al. (2007)Sample: IBD outpatients\
*N*: 396\
Mean age: 38 (SD NR)\
Male: 51%\
Origin: Czech Republic\
Design: cross-sectional\
Quality: 7/16 (43.8%)Age, gender, marital status, educational level, employment statusDisease activity, disease typeMedication typeLifestyle (smoking)UnivariateTargetIBD medications (all)MeasureSelf-reported questionnaireExtent42.6% (involuntary non-adherence) 32.5% (voluntary non-adherence)D'Inca et al. (2008)Sample: IBD outpatients\
*N*: 267\
Mean age: 41 (SD NR)\
Male: 51%\
Origin: Italy\
Design: cross-sectional\
Quality: 8/16 (50.0%)**Age,** gender, marital status, educational level, **employment statusDisease activity**, **disease duration**, disease type, clinical status**Medication type,** number of medications, dosing frequency, **multiple daily dosesForgetting, practical barriers (working day)**Univariate and multivariateTargetOral and rectalMeasureSelf-reported questionnaireExtent39%Ediger et al. (2007)Sample: IBD population\
*N*: 326\
Mean age: 41 (SD = 14.06)\
Male: 40%\
Origin: Canada\
Design: cross-sectional\
Quality: 15/16 (93.8)**Age**, **gender**, marital status, educational level, **employment statusDisease type**, disease activity, disease duration**Medication type,** dosing frequencyAnxiety (HAQ), treatment concerns, treatment necessity, mastery, **personality (agreeableness,** openness, conscientiousness, extraversion, neuroticism**), practical barriers**MultivariateTargetIBD medication not specifiedMeasureSelf-reported questionnaire (MARS)Extent35%\
(27% men; 37% women)Goodhand et al. (2013)Sample: IBD outpatients\
*N*: 144\
Mean age: adults-40 (SD = 1.5); young adults-20 (0.2)\
Male: adults-62%, young adults-51%\
Origin: UK\
Design: cross-sectional\
Quality: 8/16(50%)**Age**, gender, ethnicity, marital status, employment status, education level, **SES**Co-morbidity, disease duration, Disease type (CD, UC, IBDU), **disease activity,** **age at diagnosis**, hospital visits (OPC, hospital admissions)Daily dose frequency, pill Burden (no of pills per day), medication type, concomitant medicationsAnxiety, **depression,** Lifestyle (smoking, alcohol)Univar ate and MultivariateTargetThiopurineMeasureSelf-reported questionnaire (Morisky Medication Adherence Scale---MMAS-8)\
6-TGN levelsExtent12%Hovarth et al. (2012)Sample: IBD outpatients\
*N*: 592 CD\
Median age: 38 (15--81)\
Male: 46%\
Origin: Hungary\
Design: cross-sectional\
Quality: 7/16 (44%)Gender, educational levelDisease type, disease activity, functional disability, CAM use, previous surgeries**Medication type** (**immunomodulator use**)H-QoL, need for psychologist, Lifestyle (smoking)UnivariateTargetAminosalicylates, corticosteroids, immunomodulators, biological therapyMeasureSelf-reported questionnaireExtent13.4%Horne et al. (2009)Sample: Members of the National Association for Colitis and Crohn's disease (NACC)\
*N*: 1871\
Mean age: 50.1 (SD = 15.9)\
Male: 37%\
Origin: USA\
Design: cross-sectional\
Quality: 12/16 (75.5%)**Age**, genderDisease type, **disease duration**, GP visits, **outpatient visits**, inpatient visits**Treatment necessity, treatment concerns**, **attitudinal group**MultivariateTargetIBD medications not specifiedMeasureSelf-reported questionnaire (MARS)Extent28% (unintentional) 32% (altered dose) 17% (stopped)Kamperidis et al. (2012)Sample: IBD outpatients\
*N*: 189\
Mean age: 38 (SD = 1.0)\
Male: 55%\
Origin: USA\
Design: cross-sectional\
Quality: 8/14 (57.1%)**Age**, gender, ethnicity, **SESDisease type**, disease activityConcomitant medicationUnivariate and multivariateTargetBiologicsMeasureThiopurine in urineExtent8%Kane et al. (2001)Sample: IBD outpatients\
*N*: 94\
Median age: 42.5 (range 18--79)\
Male: 51%\
Origin: USA\
Design: cross-sectional\
Quality: 6/14 (42.9%)Age, **gender**, **marital stat us**, employment status, insurance type**Disease activity**, **recent endoscopy,** family history, length of remission**Concomitant medication**QOLUnivariate and multivariateTargetOral NSAID (5-ASA)MeasureMED-TOTAL formula---refill and patient recordsExtent60.0%Kane (2006)Sample: CD outpatient database\
*N*: 274\
Age: NR\
Male: 42.3%\
Origin: USA\
Design: retrospective cohort\
Quality: 7/16 (43.8%)Age, **gender (female)**, ethnicity, marital status, education, insurance type, area codeDisease type,\
**time since 1st infusion (\>18** **weeks)**Concomitant medicationUnivariate and multivariateTargetInfliximab (biologic)MeasureClinic appoint no showExtent15.0% (at least one no show)Kane et al. (2009)Sample: CD patients on national database\
*N*: 571\
Mean age: 38.5 (15.0)\
Male: 45%\
Origin: USA\
Design: Longitudinal\
Quality: 9/16 (56.3%)Age, genderCo-morbidities, hospitalization, Outpatient visit, **healthcare resource utilization and costs**Concomitant medicationsNRUnivariate and multivariateTargetBiologic (Infliximab)MeasurePrescription refillsExtent34.3%Kane et al. (2011)Sample: CD patients on national database\
*N*: 44,191\
Mean age: NR\
Male: 37.3%\
Origin: USA\
Design: longitudinal\
Quality: 4/14 (28.6%)**Medication type**NRUnivariateTargetOral NSAID (5-ASA, balsalazide + olsalazine)MeasurePrescription refill ratesExtent87% (at 12 months)Lachaine et al. (2013)Sample: UC patients: Prescription claims database\
*N*: 12,756\
Mean age: 55.3 (SD = 17.8)\
Male: 43%\
Origin: Canada\
Design: retrospective longitudinal\
Quality: 7/12 (58%)**Age**, **genderCo-morbidities**Time of corticosteroids use (previous, **current**)MultivariateTarget5-ASAMeasureMPR (Medication Possession Ratio)Extent80% + adherence at 12 months: 27.7%\
Persistence at 12 months: 45.5%Lakatos (2009)Sample: IBD outpatients\
*N*: 655\
Mean age: 44.9 (SD = 15.3)\
Male: 46%\
Origin: Hungary\
Design: cross-sectional\
Quality: 9/116 (56.3%)**Educational level (CD only)**Disease duration, **previous surgery (CD only)**, **last follow-up visit (CD only)**Concomitant medicationsUnivariate and multivariateTargetOral and biologicMeasureSelf-reported questionnaireExtentCD: 20.9%\
UC: 20.6%Linn et al. (2013)Sample: IBD outpatients\
*N*: 68\
Mean age: 40.5 (SD = 14.9)\
Male: 38%\
Origin: The Netherlands\
Design: prospective\
Quality: 11/16 (68.8%)**Age**, educationMedication type**Recall of medical information**MultivariateTargetAzathioprine, 6-mercaptopurine, Infliximab\
Methotrexate, 6-thioguanine, or AdalimumabMeasureSelf-reported questionExtentMean adherence (SD) = 9.1 (1.2) (range 1--10)Mantzaris et al. (2007)Sample: IBD outpatients\
*N*: 28\
Mean age: 34.6 (SD = 9.2)\
Male: 46.6%\
Origin: Greece\
Design: prospective\
Quality: 8/16 (50.0%)Age, **gender**, **marital status**Family history, disease location, disease duration, prior surgery, disease activity**Concomitant medications**Lifestyle (smoking), QOLUnivariateTargetOral (azathioprine)MeasureSelf-reported number daily pillsExtent74.3%Mitra et al. (2012)Sample: UC patients from insurance claims database\
*N*: 1693\
Mean age: 42.3 (SD = 12.8)\
Male: 50.4%\
Origin: US\
Design: retrospective longitudinal\
Quality: 8/12 (66.7%)Age, **gender**, **geographic region**, health plan type, insurance type**Healthcare costs, healthcare utilization**, **co-morbidity**MultivariateTarget5-ASAMeasureMPRExtent72%Moradkhani et al. (2011)Sample: convenience sample from IBD support group forum\
*N*: 111\
Mean age: 31 (SD = 8.5)\
Male: 22.5%\
Origin: USA\
Design: cross-sectional\
Quality: 11/16 (68.8%)Age, gender, ethnicity, SES, employment, education, marital statusDisease type, disease activity (pt rating and physician), disease duration, setting of IBD careDisease understanding,UnivariateTargetIBD medications not specifiedMeasureSelf-reported questionnaire (Morisky)ExtentMean score 1.68 (SD = 1.43)Moshkovska et al. (2009)Sample: IBD outpatients\
*N*: 169\
Mean age: 49 (SD NR)\
Male: 51%\
Origin: UK\
Design: cross-sectional\
Quality: 9/16 (56.3%)**Age**, gender, **ethnicity,** SESDisease durationMedication type, **treatment centerTreatment necessity, treatment concerns,** satisfaction with information about medicines (SIMS) \[**HCP--patient relationship**\]Univariate and multivariateTargetNSAID (5-ASA)MeasureUrine and self-reported questionnaireExtent40% (urine), 34% (self-report)Nahon et al. (2011)Sample: IBD outpatients\
*N*: 1663\
Mean age: 31 (SD = 8.5)\
Male: 22.5%\
Origin: USA\
Design: cross-sectional\
Quality: 7/16 (43.8%)**Age**, gender, marital status, educational level, SESDisease type, disease activity, disease duration, disease severity, surgery anoperineal location, family history**Medication type,** **complicated dosing regimen,** number of tablets, lack of physician info, **impact of schedule on daily lifeLifestyle (smoking), anxiety, mood,** depression, feeling well, **patient association member**Univariate and multivariateTargetIBD medications not specifiedMeasureSelf-reported questionnaire (visual analog scale)Extent10.4%Nahon et al. (2012)Sample: IBD patients\
*N*: 1663\
Mean age: 43.6 (SD = 15.4)\
Male: 26%\
Origin: France\
Design: cross-sectional\
Quality: 7/15 (46.7%)**Anxiety**, depressionUnivariate and multivariateTargetImmunosuppressant, aTNF-a, 5-ASA, corticosteroidsMeasureSelf-reported (VAS)Extent10%Nguyen et al. (2009)Sample: IBD outpatients\
*N*: 235\
Mean age: 42.2 (SD = 14.2)\
Male: 43%\
Origin: USA\
Design: cross-sectional\
Quality: 10/16 (62.5%)**Age**, gender, **ethnicity**, educational level, marital status, employment status, health insuranceDisease severity, **disease type,** **attained age**Concomitant medication**HCP--patient relationship,** QOLUnivariate,\
multivariateTargetIBD medications not specifiedMeasureSelf-reported questionnaireExtent35.0%Nigro et al. (2001)Sample: IBD outpatients\
*N*: 85\
Mean age: Not stated\
Male: 45%\
Origin: Italy\
Design: cross-sectional\
Quality: 9/16 (56.3%)NR**Disease duration, disease severityPsychiatric disorder** \[**emotional well-being**\]Univariate and multivariateTargetIBD medications not specifiedMeasureSelf-reported questionnaireExtent7.0% non-compliant; 10.5% partial (details not provided)Robinson et al. (2013)Sample: IBD patients from drug records\
*N*: 568\
Mean age: 56 (SD = NR)\
Male: 51%\
Origin: UK\
Design: retrospective cohort\
Quality: 8/12 (66.7%)**Relapse history**Medication type, treatment switchesTargetMesalazine formulationsMeasureMPRExtent61%San Román et al. (2005)Sample: IBD outpatients\
*N*: 40\
Mean age: 39.4 (SD = NR)\
Male: 50%\
Origin: Spain\
Design: cross-sectional\
Quality: 4/16 (25.0%)Age, gender, education level, SES**Disease type** **disease duration**, symptom duration, **disease activity**Medication type, medication dose, treatment schedule**QOL**, **depression, HCP--patient relationship (discordance and trust), treatment understanding**UnivariateTargetTopical, oral, biologics (infliximab, adalimumab)MeasureSelf-reported questionnaireExtent72%Selinger et al. (2013)Sample: IBD outpatients\
*N*: 356\
Mean age: Australia-47 (SD = NR), UK-46.8 (SD = NR)\
Male: Australia 45%, UK-38%\
Origin: Australia and UK\
Design: cross-sectional\
Quality: 11/16 (68.8%)Gender, patient source (hospital clinic, office), marital status, employment, ethnicity, educational level, income**Disease type,** disease duration, hospital admissions**Concomitant medication, medication type**Anxiety, depression, **QoL**, disease knowledge, **necessity beliefs**, treatment concerns, **support group membership**MultivariateTarget5-ASA, thiopurines, biological agentMeasureMARSExtent28.7%Selinger et al. (2014)Sample: IBD patients from claims database\
*N*: 12,592\
Mean age: 49 (SD = NR)\
Male: 42%\
Origin: US\
Design: longitudinal\
Quality: 7/12 (58.3%)Age, gender**Medication type**UnivariateTarget5-ASAMeasureNo prescription fill for at least 3 monthsExtentSulfasalazine 5-ASA: 22.3% (12 m), 11.9% (24 m) Non-sulfasalazine 5-ASA: 28.5% (12 m), 16.2% (24 m)Sewitch et al. (2003)Sample: IBD outpatients\
*N*: 153\
Mean age: 37 (SD = 15.1)\
Male: 43%\
Origin: Canada\
Design: prospective\
Quality: 13/16 (81.3%)**Age**, gender, educational level, income, marital status, languageDisease type, **disease duration**, **new patient status**, **disease activity**, **physician duration**, length of visit, **further test recommendation, appointment rescheduling, consulting other HCPMedication typeHCP--patient relationship**, **psychological distress**, treatment efficacy, social support, \[perceived stress, stressful events---emotional well-being\], lifestyle (smoking)Multivariate + sensitivity analysisTargetIBD medications (all)MeasureSelf-reported questionnaireExtent:41.2%Shale and Riley (2003)Sample: IBD outpatients\
N: 98\
Median age: 49 (range 17−85)\
Male: 51%\
Origin: UK\
Design: Cross-sectional\
Quality: 9/16 (56.3%)Age, gender, marital status, educational level, **employment status**Disease type, disease severity, disease duration, disease activity, relapse frequencyMedication dose, **medication frequency**, concomitant medications**Treatment efficacy**, QOL, HCP--patient relationship, **depression,** anxiety, membership of patient groupUnivariate and multivariateTargetNSAIDs (Asacol:5-ASA)MeasureSelf-reported questionnaire, urinary ASAExtentSelf-report 48%/urinary ASA 12%Taft et al. (2009)Sample: Self-reported IBD\
*N*: 211\
Mean age: 46.5 (SD NR)\
Male: 23%\
Origin: USA\
Design: cross-sectional\
Quality: 11/16 (68.8%)Age, gender, ethnicity, educational level, marital statusDisease duration, flare (frequency, duration and severity), remission of symptoms, previous surgery**Stigma**Univariate and multivariateTargetIBD medications not specifiedMeasureSelf-reported questionnaire (MTBS)ExtentMean score (SD)\
CD: 0.98 (1.19), UC: 1.02 (1.22)Waters et al. (2005)Sample: IBD outpatients\
*N*: 89\
Age: 45 (SD = 13.5)\
Male: 57%\
Origin: USA\
Design: RCT\
Quality: 9/16 (56.3%)Age, gender (female), internet use (higher use), Crohn's and Colitis Foundation Membership (not a member)Frequency of physician visitsUnivariateTargetIBD meds (all)MeasurePatient diaryExtent54%Yen et al. (2012)Sample: IBD patients from claims database\
*N*: 5644\
Mean age: 48.3 (SD = 15.4)\
Male: 47%\
Origin: Australia\
Design: longitudinal\
Quality: 8/12 (66.7%)**Age**, **gender**, **health plan type (persistence only)**, **insurance type, geographical region** (adherence only)**Never receiving specialist care, co-morbidities (persistence only)Medication type, medication administration route** (adherence only), **previous treatment** (adherence only), **no switch from index drug** (adherence)MultivariateTarget5-ASA medicationsMeasurePersistence: time to discontinuation\
Adherence: MPRExtentNon-adherence: 79%\
Discontinuation of index drug (over 12 month period): 68.7%Factors found to be associated with treatment adherence highlighted in bold*5-ASA* 5-aminosalicylic acid, *6-TGN* 6-thioguanine nucleotide, *IBDU* inflammatory bowel disease unclassified, *ASA* Acetylsalicylic acid, *aTNF* anti-tumor necrosis factor, *AZA* azathioprine, *CAM* complementary and alternative medicine, *CD* Crohn's disease, *GP* general practitioner, *HAQ* health assessment questionnaire, *HCP* health care professional, *H-QoL* health-related quality of life, *IBD* inflammatory bowel disease, *MARS* medication adherence report scale, *MMAS* Morisky medication adherence scale, *MPR* medication possession ratio, *MTBS* medication taking behavior scale, *NR* not recorded, *NSAID* non-steroidal anti-inflammatory drug, *OPC* outpatient clinic, *QOL* quality of Life, *SD* standard deviation, *SES* socioeconomic status, *SIMS* satisfaction with information about medicines, *TPMT* thiopurine *S*-methyltransferase, *UC* Ulcerative colitis, *VAS* visual analog scaleTable 3Overview of included studies: PsoriasisAuthors and YearSample characteristics, origin, and designFactors measuredAnalysisNon-adherence: target, measure and extentDemographicClinicalTreatmentPsychosocialAltobelli et al. (2012)Sample: Psoriasis outpatients\
*N*: 1689\
Age: 48.6 (SD = 15.0) men; 47.4 (SD = 15.5) women\
Male: 56.8%\
Origin: Italy\
Design: cross-sectional\
Quality: 9/16 (56.3%)Gender, age, education, marital status, employment statusPsoriasis type (disease type), age at onset, disease-duration, affected body sites and **body surface area affected**UnivariateTargetAll modalities (topical, systemic and alternative treatments)MeasureQuestionnaireExtent54.1%Bhosle et al. (2006)Sample: Psoriasis patients on Medicaid programme in North Carolina\
*N*: 186\
Median age: 41.0 (SD = 11.44)\
Male: 41.4%\
Origin: USA\
Design: longitudinal Cohort\
Quality: 9/13 (69.2%)Age, gender, ethnicity**Co-morbiditymedication type,** combination therapyMultivariate (prospective) + sensitivity analysisTargetBiologics (alefacept, efalizumab etanercept, 80% on combination therapy)MeasurePrescription refill records (MPR)Extent44.0% overall\
34.0% biologicsChan et al. (2013)Sample: Psoriasis outpatients\
*N*: 106\
Mean age: NR\
Male: 50%\
Origin: UK\
Design: cross-sectional\
Quality: 8/16 (50.0%)Age, gender, marital status, employment status, educational level**Disease severity (topical therapy only)Number of treatment types,** **medication typeLifestyle (smoking** alcohol use**)**, **treatment efficacy**, treatment satisfaction, **practical barriers** (**fed up, too busy** lotions too messy), **QoL (topical therapy only)**UnivariateTargetTopical, oral systemic, phototherapy, biologicsMeasureSelf-reported questionnaireExtent14.2%Chastek et al. (2013)Sample: Psoriasis outpatients\
*N*: 827\
Age: 43 (SD = 12)\
Male: 52--56%\
Origin: USA\
Design: retrospective Pharmacy database\
Quality: 6/12 (50.0%)Medication typeUnivariateTargetBiologics (Etanercept and adalimumab)MeasurePersistence over 12 months (Medication refills)Extent59.6% Etanercept, 57.6% AdalimumabClemmensen et al. (2011)Sample: Psoriasis outpatients\
*N*: 71\
Mean age: 43.1 (SD = 13.0)\
Male: 51%\
Origin: Denmark\
Design: Cohort\
Quality: 5/12 (41.7%)**Medication type**Multivariate (prospective)TargetBiologics (ustekinumab, adalimumab, etanercept)MeasurePatient medical records (persistence)Extent4.2% (321 days)Esposito et al. (2013)Sample: Psoriasis patients from medical/digital databases\
*N*: 650\
Mean age: 49.0 (SD = 13.1)\
Male: 66%\
Origin: Italy\
Design: retrospective cohort\
Quality: 7/12 (58.3%)Age, **gender**Disease severity (Psoriasis area and severity index)**Medication type**UnivariateTargetaTNF (adalimumab, etanercept, infliximab)MeasurePatient medical records (persistence)Extent27.4% at 2 yearsGniadecki et al. (2011)Sample: psoriasis patients\
*N*: 747\
Mean age: 45.0 (SD NR)\
Male: 67%\
Origin: Denmark\
Design: Cohort\
Quality: 6/12 (50.0%)Age, **gender**Disease duration, presence of psoriatic arthritis, Co-morbidityConcomitant medication, **prior treatment (prior use of anti-TNF), medication type**QoLMultivariateTargetBiologics (infliximab, adalimumab, etanercept)MeasurePatient medical records (persistence)Extent32.3% overall\
Infliximab 25.58%\
Adalimumab 32.0%\
Etanercept 36.2%Gokdemir et al. (2008)Sample: Psoriasis patients\
N: 109\
Mean age: 40.1 (SD = 15.2)\
Male: 44%\
Origin: Turkey\
Design: cross-sectional\
Quality: 5/14 (35.7%)Gender, **marital status,** **education level,** employment status, family history (note demographic factors not significant in multivariate analysis)Disease severityMedication typeLifestyle (smoking), QoL, **satisfaction with treatment**Univariate and multivariate (prospective)TargetTopical, oral, combined and phototherapyMeasureNumber or weight of prescribed doses taken by the patient/number or weight of doses prescribed for the patient × 100%ExtentNot givenRichards et al. (1999)Sample: Psoriasis outpatients\
*N*: 120\
Mean age: 49.0 (SD = 16.0)\
Male: 54%\
Origin: UK\
Design: cross-sectional\
Quality: 6/16 (37.5%)**Age**, gender**Age at onset**, disease duration, **disease severity**General well-being**, impact on life, interfered with life**UnivariateTargetTopical, systemic, combination and phototherapyMeasureSelf-reported questionnaireExtent39.0%Umezawa et al. (2013)Sample: Psoriasis outpatients\
*N*: 127\
Mean age: I:A:U = 52.1:50.1:62.3 (SD = 11.4:10.7:12.3)\
Male: 72%\
Origin: Japan\
Design: longitudinal\
Quality: 5/14 (35.7%)**Medication type**Univariate and MultivariateTargetInfliximab, adalimumab and ustekinumabMeasureDrug survival rate (at 12 month follow-up)ExtentProportion discontinuing (less than a year):\
Infliximab---26.3%\
Adalimumab---20.3%\
Ustekinumab---3.3%Zaghloul and Goodfield (2004)Sample: Psoriasis outpatients\
*N*: 201\
Mean age: 45.1 (SD = 10.1)\
Male: NR\
Origin: UK\
Design: longitudinal\
Quality: 4/16 (25.0%)Age, **gender,** **marital status,** **employment status,** **medication paymentDisease severity, lesion location, Number of lesionsMedication type**, **Medication frequency, previous treatment (naïve to treatment), side effectsQoL, lifestyle (smoking, alcohol consumption)**UnivariateTargetTopical and oralMeasureNumber or weight of prescribed doses taken by the patient/number or weight of doses prescribed for the patient × 100%\
Self-report interviewExtentNumber of doses or weight: 60.6%\
Self-report: 92.0%Factors found to be associated with treatment adherence highlighted in bold*aTNF* anti-tumor necrosis factor, *MPR* medication possession ratio, *NR* not recorded, *QoL* quality of life, *SD* standard deviation

The sample size of the studies varied considerably, ranging from 28 to 12,750 participants. The vast majority of studies (90.4%) were based on samples from Europe (*n* = 37, 51%) or North America (*n* = 30, 41%). Participants were derived from outpatient clinics in the majority of samples. In RC, this was 76.9% (*n* = 20), in IBD (*n* = 25, 69.4%) and in PS (*n* = 8, 72.7%). One sample in RC \[[@CR23]\] was recruited in a clinical trial and two samples in IBD \[[@CR69], [@CR79]\] were convenience samples recruited online through social media or IBD forums. The remaining samples were established cohorts drawn from medical or pharmacy databases.

The proportion of longitudinal studies (including retrospective cohorts) was 57.8% (*n* = 15) in RC, 36.1% (*n* = 13) in IBD, and 72.7% (*n* = 8) in PS. While a substantial proportion of studies had a longitudinal design, factors were most often examined as concurrent associates of adherence and not as prospective predictors. Thus, in the current review all factors are considered as potential associates of adherence.

A large proportion of studies (57.5%) used self-report measures to assess adherence. In RC, the medication event monitoring system (MEMS) was used to measure non-adherence in three studies \[[@CR28], [@CR34], [@CR44]\], others used pill counts and pharmacy refill data \[[@CR22], [@CR23], [@CR27]\] or plasma analysis \[[@CR21]\]. Five studies had a measure of medication persistence (i.e., continuation with a medication) as the adherence outcome, obtained via HCP report \[[@CR36], [@CR38]\] or patient records/case notes \[[@CR25], [@CR26], [@CR45]\]. In IBD, three studies combined self-report measurement with a biochemical measure \[[@CR39], [@CR53], [@CR59]\]. One study assessed adherence using a biological measure only \[[@CR58]\] and another via infusion appointment attendance \[[@CR12]\]. The remaining five studies used a proxy measure of adherence via prescription refill data \[[@CR41], [@CR49]--[@CR51], [@CR76]\]. In PS, two studies assessed adherence using a proxy measure from prescription refill data \[[@CR83], [@CR85]\]. A further three studies had a measure of medication persistence as the adherence outcome obtained from patient medical records \[[@CR86]--[@CR88]\]. Two studies assessed adherence with respect to unused treatment medication ascertained via pill counts weight \[[@CR89], [@CR92]\].

Quality of Included Studies {#Sec11}
---------------------------

The proportion of quality criteria met by each study varied widely across the three clinical areas, ranging between 31% and 87.5% in RC, 25% and 93.8% in IBD, and 25% and 58.3% in PS. The included studies in RC typically met the highest proportion of quality criteria, whereas those in PS met the least. Quality criteria most commonly not met related to details of the study required to enable an assessment of bias. A number of studies did not report details of eligibility criteria (*n* = 15, 20.5%) or the number of participants not consenting to participate in the study (*n* = 42, 57.5%), so it was not possible to make an assessment of biases due to participant selection. Similarly, failure to report how missing data were treated (*n* = 65, 89%) and control for confounders (*n* = 35; 52%) was common preventing an assessment of the strength of the associations found. The majority of studies did not report power calculations (*n* = 56, 77%) to estimate their sample sizes and as such it was difficult to assess whether studies were adequately powered to detect associations. However, several studies had very small sample sizes that were unlikely to result in adequate power for the statistics applied.

Overview of Findings {#Sec12}
--------------------

Adherence rates varied considerably in all clinical areas and ranged between 7% and 75% in RC, 4% and 72% in IBD, and 8% and 87% in PS. Evidence of an association of rates according to the adherence measure type (e.g., self-report, MEMs, biochemical, medication possession ratio) was not found. Factors assessed in relation to non-adherence were collated into four key categories: demographic; clinical; treatment; and psychosocial. All the factors explored across two or more chronic conditions, or in one condition and in a minimum of two studies with consistent results are presented in Table [4](#Tab4){ref-type="table"}. The table summarizes the frequency of studies examining these factors and proportion of studies to find a statistically significant association.Table 4Number of studies to examine factor and to find an association with non-adherence according to individual condition and overallFactorsRC (*N* = 26)IBD (*N* = 36)Psoriasis (*N* = 11)Overall (*N* = 73)Number of studies analyzing factorNumber of studies in finding an association (*p* \< 0.05)Number of studies analyzing factorNumber of studies finding associationNumber of studies analyzing factorNumber of studies finding association (*p* \< 0.05)Nos. of studies analyzing factorNos. of studies finding associationProportion of studies finding an association %DemographicAge228291171582034.5Gender20531783591525.4Marital status611524225520.0Education level1741913139615.4Socioeconomic status40610010110.0Employment status311234119526.3Ethnicity52820013430.8Geographical location1132004375.0Income4220006233.3Insurance type71510012216.7ClinicalDisease duration1521963037821.6Disease activity1221650028725.0Disease severity00525310550.0Co-morbidity103432116743.8Functional disability142200016212.5Family history005010600.0Symptoms7100007114.3Relapse history0061006116.7Lesion location00002222100TreatmentMedication Type144171097402152.5Dose4021117228.6Dosing frequency1163117571.4Previous treatment2111225480.0Side effects4100115240.0Concomitant medications201230014321.4PsychosocialTreatment necessity5243009555.6Treatment concerns54530010770.0Emotional well-being (anxiety or depression)53750012866.7HCP--patient relationship5443009777.8Treatment efficacy1021114250.0Treatment self-efficacy33000033100Practical barriers3222116583.3Support group/society member, internet users (IBD)4032007228.6General health status4100104125.0Quality of life11624211545.5Disease or treatment understanding2042005240.0Lifestyle (smoking)31814215426.7Illness beliefs200000000.0*RC* rheumatologic conditions, *IBD* inflammatory bowel disease

Demographic Factors {#Sec13}
-------------------

Age and gender were the most commonly examined factors (79.5% and 80.8%) in relation to adherence across conditions. The majority of studies to examine them (*n* = 38, 65.5% and *n* = 44, 74.6%, respectively) found no association with adherence and, where these were found, the findings were not consistent. The exception was for IBD where older age was found to be associated with greater likelihood of adherence in all studies to find an association (*n* = 11). However, an association was found in only a minority of the IBD studies; the majority (i.e., 18 out of 29) found age not to be associated with adherence. Marital status, education level, socioeconomic status, employment status, income, insurance type, geographical location and ethnicity were not consistently associated with non-adherence across diseases.

Clinical Factors {#Sec14}
----------------

Clinical factors were the second most commonly examined (see Table [4](#Tab4){ref-type="table"}). Disease duration and disease activity were the two clinical factors examined most frequently (*n* = 37 and *n* = 28). However, only a small proportion of these studies (21.6% and 25%) found an association with adherence, and where associations were found, the relationship was not found to be consistent. In some cases, the relationship between disease duration and activity was positively associated with adherence, while in others there was a negative association. Disease severity and lesion location, although only examined in a minority of studies (*n* = 10 and *n* = 2), reported the most consistent associations. In the PS studies, disease severity was the most commonly examined clinical factor in relation to adherence (45.5%). An association with adherence was found in three of these studies (60%), in which patients with lower disease severity were more likely to be non-adherent to their PS treatment than those with greater disease severity \[[@CR84], [@CR90], [@CR92]\]. Only two of the five IBD studies (40%) to examine this reported an association between disease severity and adherence and the direction of this association conflicted. None of the included RC studies examined disease severity.

Location of psoriatic lesions was examined in two of the PS studies (18%). Non-adherence was found to be more likely among patients with facial lesions compared to those with lesions restricted to the rest of the body or with increasing number of lesion sites \[[@CR92]\] and among those with greater body surface area of lesions \[[@CR72]\]. Further details about these studies are available in the Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}.

Treatment Factors {#Sec15}
-----------------

Medication type, dosing frequency, and previous treatment showed the most frequent association with adherence in the treatment category. Medication type was the most commonly explored treatment factor, which was assessed in 40 studies (54.8%) with an association to non-adherence reported in over half of these studies (52.5%).

In RC, non-steroidal anti-inflammatory drugs (NSAIDs) were found to be associated with lower adherence levels than disease-modifying medications \[conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)\] in one study \[[@CR28]\]. Another study found an association only for patients on steroids with these more likely to be adherent than those patients on NSAIDs or csDMARDs \[[@CR40]\], although no association with corticosteroid use was observed in the other study examining this \[[@CR36]\]. Among anti-tumor necrosis factor (TNF) treatments, significantly higher discontinuation rates and lower adherence levels were found for the biologic infliximab compared to the biologic etanercept and adalimumab \[[@CR31], [@CR38]\].

In IBD, greater adherence was associated with patients receiving anti-TNF (versus Prednisolone, Budesonide, exclusive enteral nutrition and 5-aminosalicylic acid (5-ASAs) \[[@CR58]\], immunomodulator (versus 5-ASA) \[[@CR46], [@CR54], [@CR56]\], and steroid treatments compared to those who prescribed other medications (including 5-ASAs, immunosuppressants and antibiotics) \[[@CR74]\]. In another study, non-adherence was reported to be more frequent in treatment with 5-ASAs compared to treatment with thiopurines and biological therapy \[[@CR75]\]. Patients on oral treatment were more likely to be adherent compared to those on topical and enema treatments in another study \[[@CR53]\].

Persistence rates were significantly higher for patients taking non-sulfasalazine 5-ASA compared to those taking sulfasalazine 5-ASA in one study \[[@CR76]\], whereas in another study persistence was higher for those prescribed a multi-matrix system mesalamine 5-ASA compared to those prescribed balsalazide, mesalamine delayed release or sulfasalazine 5-ASAs \[[@CR81]\]. In PS, six studies looked for associations according to biological DMARD, with higher persistence to adalimumab or etanercept compared to infliximab in one study \[[@CR88]\], higher persistence to etanercept compared to both adalimumab and infliximab in another study \[[@CR87]\] and higher persistence to ustekinumab compared with other anti-TNFs found in two studies \[[@CR86], [@CR91]\]. The other two studies found no difference in levels of adherence between adalimumab and etanercept \[[@CR85]\] or between alefacept, efalizumab or etanercept \[[@CR83]\].

The number of doses taken daily was explored in seven studies across the diseases, of which the majority found an association (71.4%, *n* = 5). While the dosing frequencies examined varied between studies, associations were consistent, in that a greater likelihood of adherence to treatment was found with less frequent dosing.

Previous treatment was explored in five studies, four of which found an association with adherence (80%). Three of these studies reported that previous exposure to the same drug or similar type of treatment increased the likelihood of non-adherence/early discontinuation \[[@CR31], [@CR88], [@CR92]\]. This may be due to confounding factors such as lack of efficacy or acquired resistance to the drug class. The remaining study, reported that not having used rectal 5-ASA or immunosuppressive/biologic agents, was associated with the risk of non-persistence and non-adherence to 5-ASAs \[[@CR81]\].

Psychosocial Factors {#Sec16}
--------------------

Thirteen psychosocial factors were examined in relation to adherence (see Table [4](#Tab4){ref-type="table"}). Psychosocial factors were most commonly examined in the studies of IBD, followed by RC and were rarely examined in studies of PS. Treatment beliefs (i.e., necessity, concerns and efficacy), emotional well-being (depression and anxiety), HCP--patient relationship, treatment self-efficacy (i.e., confidence in one's ability to follow treatment) and practical barriers (e.g., frequent traveling, forgetfulness, etc.) were found to be associated with non-adherence in at least 50% of the studies to examine these. Non-adherence was found to be associated with doubts about treatment necessity in 55.6% of the studies to examine this \[[@CR29], [@CR40], [@CR57], [@CR68], [@CR75]\]. Similarly, concerns about side effects and low perception of treatment efficacy were found to be associated with non-adherence in 70% and 50% of studies to examine this, respectively \[[@CR29], [@CR33], [@CR39], [@CR40], [@CR57], [@CR68], [@CR78], [@CR84]\]. Four of the ten studies in RC and IBD to examine depression found a consistent association with non-adherence, with greater non-adherence reported amongst patients with depression or depressive symptoms. For anxiety, while over a third of the studies to examine this (*n* = 3, 37.5%) found an association with non-adherence, the direction of association was inconsistent. No studies assessed depression or anxiety in patients with PS. Practical barriers (e.g., frequent traveling, forgetfulness, etc.) were explored in six studies, and five of these found non-adherence to be more likely when practical barriers to taking treatment were perceived to be present. There was also some evidence that low levels of trust and satisfaction in the HCP--patient relationship may increase treatment non-adherence, with an association reported in 77.8% of the studies to examine this \[[@CR32], [@CR37], [@CR40], [@CR43], [@CR71], [@CR74], [@CR77]\]. This factor was not examined in any of the PS studies. Lower treatment self-efficacy was significantly and consistently associated with poorer medication adherence in all three studies of RC \[[@CR23], [@CR28], [@CR39]\]. This factor was not examined in any of the IBD or PS studies.

Discussion {#Sec17}
==========

This is the first review to systematically examine factors associated with non-adherence to treatment specifically for patients with selected IMIDs across three clinical areas. Demographic factors were the most commonly examined in relation to non-adherence followed by clinical and treatment factors. Psychosocial factors were examined in a minority of studies in RC and IBD and rarely examined in the PS studies. However, several consistent associations with adherence were observed for psychosocial factors that appear independent of the therapeutic area assessed.

While examined most commonly, none of the demographic or clinical factors were found to be consistently associated with non-adherence. Despite the general beliefs that some demographic factors are associated with non-adherence, this finding is in line with the other systematic literature reviews, where there is no consistent relationship between demographic characteristics and adherence in patients with chronic conditions \[[@CR2]--[@CR4]\]. Of the demographic factors, there was some evidence of an association between older age and adherence to IBD treatments; however, further studies are necessary to fully determine this.

With the clinical factors, there was some evidence that treatment non-adherence may be more likely among patients with PS with greater number/body surface area of lesions and among those with facial lesions in both studies to examine them. While the association of greater non-adherence with increased lesion coverage may appear counterintuitive, the visibility of psoriatic lesions to others well-being is put forward as a main stigmatizing factor from the patients' perspective which may have a significant impact on perceptions of body image and well-being \[[@CR93]\], thus it is possible that the observed association is mediated by psychosocial factors such as anxiety or depression, the effects of which are discussed below. However, it is important to note the observed association is based on only two studies rated to be of medium to low quality.

Some evidence of an association was also found with the treatment factors including frequency of dosing and medication type. Due to wide heterogeneity in the medication types assessed, and scarce comparison studies among drug classes and between oral and injectable medications, it is not possible to draw conclusions as to which types of medication are associated with greater non-adherence. Consistent with some earlier studies \[[@CR94], [@CR95]\], less frequent dosing was associated with increased adherence, which may reflect the lower demand on memory and planning for the patient. However, it was not possible to assess whether there was a dosing frequency above which the likelihood of treatment non-adherence is increased, again due to wide heterogeneity in dosing frequencies assessed.

Psychosocial factors were only explored in a minority of studies. Despite heterogeneity in measures used, several consistent associations were observed. In particular, the current review found evidence that lower perceptions of treatment necessity \[[@CR29], [@CR40], [@CR57], [@CR68], [@CR75]\] and of treatment efficacy \[[@CR78], [@CR84]\], greater treatment concern \[[@CR39], [@CR78], [@CR84]\] and higher HCP--patient discordance \[[@CR32], [@CR37], [@CR40], [@CR43], [@CR71]\] were associated with greater likelihood of non-adherence. Similar associations have been observed for necessity and concern beliefs about medication and the HCP--patient relationship in previous reviews of adherence in IBD and RA specifically \[[@CR3], [@CR13], [@CR15], [@CR17]\], as well as in a systematic review across multiple conditions \[[@CR96]\]. This suggests that addressing treatment concerns, increasing understanding of treatment necessity, and enhancing HCP--patient communication may be paramount to facilitate treatment adherence, irrespective of the type of IMID.

Evidence of an association of poorer emotional well-being, particularly depression, with non-adherence was found in the current review. Associations between anxiety and non-adherence on the other hand were less consistent, indicating that if an association exists, this may be weaker. These findings are consistent with those of a systematic review of studies of patients across a range of chronic conditions \[[@CR97]\]. Both reviews suggest that depression but not anxiety may be a risk factor for treatment non-adherence in IMIDs, as well as chronic conditions more generally. This finding is of high importance, as depression is a potentially modifiable factor if diagnosed and treated appropriately, thus reducing the likelihood of poor adherence. It also raises an important question about the nature of the process in this effect. For example, depression might have effects on memory and planning ability, as well as on beliefs about treatment and efficacy \[[@CR97], [@CR98]\].

Treatment self-efficacy may also be an important factor for treatment adherence. Thus, patients with stronger beliefs in their ability to follow treatment were found to be more likely to adhere than those with comparatively weaker self-efficacy beliefs. Although, this was only examined in studies of RC, previous systematic reviews have found treatment self-efficacy to be closely related to adherence in a number of different chronic conditions \[[@CR96]\]. However, to enable firm conclusions to be drawn, further research is needed to investigate these factors among patients specifically with PS and IBD.

Evidence of an impact of practical barriers in treatment adherence was also found in the current review. The category of practical barriers is broad and can encompass many different types. The application of some topical creams in PS, for example, presents physical and possibly social barriers to administering treatment. Frequent traveling, busy lifestyles or forgetfulness may present time- and routine-related barriers. While these barriers on the surface may appear to be unintentional drivers of non-adherence, recent research has shown that patient perceptions of unintentional factors can be predicted by medication beliefs (intentional non-adherence factors \[[@CR99]\]). This suggests that practical barriers may reflect in part reduced motivation to take treatment, and, as such, addressing treatment beliefs would also be necessary to overcome them. For this reason, practical barriers are incorporated into the broader category of psychosocial risk factors.

Limitations and Recommendations for Future Research {#Sec18}
---------------------------------------------------

Limitations to this review and the quality of the available evidence should be taken into account when interpreting the findings. For example, it was not possible to draw conclusions regarding factors associated across a range of RCs, as the majority of studies eligible for inclusion were found for the condition RA. Similarly, it was not possible to draw conclusions as to whether factors associated with biologic systemic treatments were comparable to those of other classes of treatment, due to the lack of studies to examine this. Further, the majority of the assessed studies relied on patient-reported data and thus subjective measures of adherence, which may not be an accurate reflection of true level of non-adherence. In addition, psychosocial factors were only explored in a minority of studies. As evidence for psychosocial factors was the most consistent, it is important for further research to focus on understanding the nature and strength of the relationship of these factors with treatment adherence. In particular, there is a strong need for prospective longitudinal studies to determine whether the factors identified in the current review predict treatment non-adherence or are related in another way. Similarly, there is also a need for intervention studies in which these factors are modified to see whether this results in improved adherence.

The high level of heterogeneity in both the measures and analysis approaches applied across studies limits the conclusions that can be drawn from the synthesis of the data. Although the type of measure did not correlate with the overall level of adherence found, it was not possible to determine whether the pattern of associations varied according to the adherence measure used. There was wide variation in the quality of the studies, which may have influenced the pattern of findings. Studies investigating adherence across a range of IMID conditions using the same measures and analysis approach are urgently needed to enable identification of common and consistent predictors. Efforts to address such limitations are currently underway in the ALIGN study; a multi-country, cross-section AL study to determine patient specific and General beliefs towards medication and their treatment adherence to selected systemic therapies in chronic inflammatory diseases (IMID) (UKCRN ID: 12782). It is anticipated that the results of this study will build on the findings of this review and further advance our understanding of the role of factors particularly those of patient beliefs about treatment for adherence to systemic therapies.

Implications for Clinical Practice {#Sec19}
----------------------------------

Although the heterogeneity of the reviewed studies restricts our ability to draw firm conclusions, fairly minimal evidence was found for an impact of demographic, clinical and treatment factors on treatment non-adherence, but more consistent evidence was reported for psychosocial factors. The findings of the current review indicate that greater treatment concern, lower treatment self-efficacy and necessity, presence of depression or practical barriers, and a sub-optimal HCP--patient relationship may have a negative impact on treatment adherence, and these could be considered modifiable risk factors. At present, assessing adherence is not always high priority within clinical practice, due in part to a combination of time constraints and lack of awareness regarding the extent and nature of the problem. Even when adherence is measured, the rates can be of limited value without the understanding of potential risk factors, and most importantly, interventions to address and modify these psychosocial factors. Increasing clinician awareness of the adherence problem, however, does not always result in changes to patient beliefs and behavior \[[@CR100]\]. Twofold intervention, that focuses on increasing clinician awareness about the range of factors, particularly psychosocial that may impact on treatment non-adherence as well as tools to help tackle these issues, are thus likely to be most effective. For example, the development of tools to help clinicians elicit and address patient beliefs in routine consultations is recommended.

Conclusions {#Sec20}
===========

Through a systematic analysis of the evidence across the clinical areas of RC, IBD and PS, this review has identified common patterns to both focus research efforts and to support the development of tools or interventions in routine care to help patients follow their prescribed treatment regimen. To date, the main focus of research in the areas of RC, IBD and PS has been on the association of demographic factors, and clinical or treatment factors. The findings of the current review, however, suggest that these factors are not consistent or key determinants of adherence. It appears that psychosocial factors are more consistently associated with adherence. As such, interventions designed to modify these factors through addressing treatment beliefs, providing practical advice on taking treatment, and improving communication between HCPs and patients may prove to be the most effective.
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